A. Legal Requirement, Guidance for the Notification of Serious Breaches of GCP or the Trial Protocol Version 6, 08 Jul 2020, MHRA
Regulation 29A of the Medicines for Human Use (Clinical Trials) Regulations 2004 [Statutory Instrument 2004/1031], as amended by Statutory Instrument 2006/1928, contains a requirement for the notification of “serious breaches” of GCP or the trial protocol:
“29A. (1) The sponsor of a clinical trial shall notify the licensing authority in writing of any serious breach of –
(a) the conditions and principles of GCP in connection with that trial; or
(b) the protocol relating to that trial, as amended from time to time in accordance with regulations 22 to 25, within 7 days of becoming aware of that breach.
(2) For the purposes of this regulation, a “serious breach” is a breach which is likely to effect to a significant degree –
(a) the safety or physical or mental integrity of the subjects of the trial; or
(b) the scientific value of the trial”.
Back to the index of the Guidance for the Notification of Serious Breaches of GCP or the Trial Protocol Version 6, 08 Jul 2020, MHRA, Medicines & Healthcare products Regulatory Agency
Clinical Research News
Upcoming Clinical Research Training and Conferences
-
on demandACROSS Global Training AcademyOnline
-
29 September 2023 – 02 October 2024SCDM (Society of Clinical Data Management)United States
-
21 – 23 May 2024InformaBelgium
-
03 – 04 June 2024The Society for Clinical Research Sites (SCRS)United States
-
16 – 17 July 2024The Society for Clinical Research Sites (SCRS)Australia
-
27 September – 29 October 2024The Society for Clinical Research Sites (SCRS)United States
Próximos ensaios clínicos
-
Fondazione Policlinico Universitario Agostino Gemelli...Ainda não está recrutando
-
National Taiwan University HospitalNational Taiwan University Hospital Bei-Hu BranchRecrutamentoCanulação bem sucedidaTaiwan
-
University of British ColumbiaMcMaster UniversityAinda não está recrutando
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...RecrutamentoAldosteronismo primário | Antagonista do Receptor Mineralocorticóide | FinerenonaChina
-
Zoya Haitov Ben ZikriRecrutamentoExtração de dentes do siso ou implante de mandíbulaIsrael
-
Cairo UniversityRecrutamento
-
AstraZenecaMerck Sharp & Dohme LLCRecrutamentoCâncer de Próstata Metastático Resistente à CastraçãoAlemanha
-
University Hospital, MotolAinda não está recrutandoDiabetes mellitus tipo 1 | Diabetes mellitus tipo 1 com hipoglicemia | Dirigir
-
University of LouisvilleAinda não está recrutandoLesão MiocárdicaEstados Unidos
-
University of MiamiRecrutamento
-
University of ConnecticutYale UniversityAinda não está recrutando
-
Pamukkale UniversityAinda não está recrutandoSíndrome pré-menstrual | Risada